aTyr Pharma, Inc.(ATYR)

$0.65▲0.06 (10.36%)

Chart

aTyr Pharma, Inc.(ATYR)

NASDAQ

$0.65▲0.06 (10.36%)

Chart Studio

ATYR(ATYR)

ATYR

Overview Notebook Intelligence Chart History Fundmntls TTM Earnings Analysts News Financials Segments Insiders Institl.DCF Peers

Q3 2026 EPS Estimate

$-0.15

Aug 6, 2026 · Reports before open

FY2030E EPS$0.47

Analyst Sentiment

Wall St. Consensus

Hold

9 analysts·Limited coverage

Score

3 Buy (33%)6 Hold (67%)0 Sell (0%)

Rating Breakdown

Strong Buy

00%

Buy

333%

Hold

667%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear

$1.00

+52.9%

Consensus

$1.25

+91.2%

Bull

$17.00

+2499.8%

12-Month Target Range9 analysts

$1.00$1.25$17.00

Current $0.65Consensus

Current Price

$0.65

Upside to Consensus

$0.60

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)

FY2027

Rev+127.95%

EPS—

FY2028

Rev+498.96%

EPS—

FY2029

Rev+280.07%

EPS—

Raw consensus estimates (low / average / high) from covering analysts.

Annual

Metric	FY2026E	FY2027E	FY2028E	FY2029E	FY2030E
Revenue Avg	$4M	$9M	$53M	$200M	$201M
Low	$4M	$9M	$53M	$200M	$201M
High	$4M	$9M	$53M	$200M	$201M
EBITDA Avg	$-2M	$-5M	$-32M	$-120M	$-120M
Low	$-2M	$-5M	$-32M	$-120M	$-120M
High	$-2M	$-5M	$-32M	$-120M	$-120M
EBIT Avg	$-2M	$-5M	$-32M	$-120M	$-120M
Low	$-2M	$-5M	$-32M	$-120M	$-120M
High	$-2M	$-5M	$-32M	$-120M	$-120M
Net Income Avg	$-54M	$-60M	$-76M	$-39M	$44M
Low	$-55M	$-68M	$-91M	$-39M	$44M
High	$-51M	$-52M	$-33M	$-39M	$44M
EPS Avg	$-0.57	$-0.65	$-0.60	$-0.42	$0.47
Low	$-0.59	$-0.73	$-0.98	$-0.42	$0.47
High	$-0.55	$-0.56	$-0.35	$-0.42	$0.47
Analysts (Rev / EPS)	6 / 4	6 / 6	8 / 7	7 / 2	7 / 5

Quarterly

Metric	Q3 2026	Q4 2026	Q1 2027	Q2 2027	Q3 2027	Q4 2027
Revenue Avg	$3M	$10M	—	$8M	$19M	$44M
Low	$3M	$10M	—	$8M	$19M	$44M
High	$3M	$10M	—	$8M	$19M	$44M
EBITDA Avg	$-2M	$-6M	—	$-5M	$-11M	$-26M
Low	$-2M	$-6M	—	$-5M	$-11M	$-26M
High	$-2M	$-6M	—	$-5M	$-11M	$-26M
EBIT Avg	$-2M	$-6M	—	$-5M	$-11M	$-26M
Low	$-2M	$-6M	—	$-5M	$-11M	$-26M
High	$-2M	$-6M	—	$-5M	$-11M	$-26M
Net Income Avg	$-14M	$-16M	$-17M	$-19M	$-18M	$-18M
Low	$-15M	$-16M	$-17M	$-19M	$-18M	$-18M
High	$-13M	$-16M	$-17M	$-19M	$-18M	$-18M
EPS Avg	$-0.14	$-0.16	$-0.17	$-0.19	$-0.18	$-0.18
Low	$-0.15	$-0.16	$-0.17	$-0.19	$-0.18	$-0.18
High	$-0.13	$-0.16	$-0.17	$-0.19	$-0.18	$-0.18
Analysts (Rev / EPS)	5 / 4	5 / 2	— / 2	5 / 1	5 / 1	5 / 2

Earnings Surprises

Recent Analyst Actions

Sep 15, 2025RBC Capital

aTyr Pharma downgraded to Sector Perform from Outperform at RBC Capital

Target:$1.50

+47.8%from $1.01

Sep 15, 2025Wells Fargo

aTyr Pharma downgraded to Equal Weight from Overweight at Wells Fargo

Target:$1.00

-1.5%from $1.01

Sep 15, 2025Leerink Partners

aTyr Pharma downgraded to Market Perform from Outperform at Leerink

Target:$1.00

-1.5%from $1.01

Aug 22, 2025Jefferies

aTyr Pharma price target raised to $17 from $9 at Jefferies

Target:$17.00

+217.8%from $5.35

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance